Short Summary
Azurity Pharmaceuticals failed to convince the PTAB that EXELIXIS's drug formulation patent was unpatentable, resulting in a denial of institution for IPR2025-00210. The Board rejected anticipation arguments based on prior art family relationships and dismissed obviousness claims regarding impurity control.
Detailed Summary
The Petitioner, Azurity Pharmaceuticals, Inc., sought to invalidate EXELIXIS, INC.'s patent (11298349) covering drug formulation/process chemistry via Inter Partes Review (IPR). The Board denied institution because the Petitioner failed to demonstrate a reasonable likelihood of success. Specifically, regarding anticipation under 102, the Board ruled that prior art cited from the same patent family did not qualify as effective prior art against the '349 patent. Furthermore, while the Petitioner argued obviousness (103) by combining Brown, Kubo, and Remington to control a specific impurity, the Patent Owner successfully countered this by citing district court findings regarding the lack of motivation for such control under the cited process.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Azurity Pharmaceuticals, Inc. vs EXELIXIS, INC. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Meta Platforms, Inc.vsResonant Systems, Inc.
Meta Platforms petitions the PTAB to invalidate claims 2 and 3 of Resonant’s ’337 haptic‑feedback patent, arguing obviousness over multiple prior‑art references and seeking to join Apple’s parallel IPR.
Solventum CorporationvsM.E.A.C. Engineering Ltd.
Solventum Corporation filed a petition challenging 22 claims of the '534 Patent owned by M.E.A.C. Engineering Ltd., asserting that they are anticipated under 35 U.S.C. § 102. Petitioner argues that the prior art reference, Bitel (WO 03/030966), discloses every element of the claimed negative pressure wound therapy system.
ClearCorrect Operating, LLC et al.vsAlign Technology, Inc.
The PTAB affirmed all claims of Align Technology’s ‘630 patent after finding ClearCorrect’s obviousness arguments unpersuasive. No claim was deemed unpatentable.
PacifiCorp et al.vsMES, Inc.
WEC Energy Group and Birchtech Corp. filed a joint motion asking the PTAB to keep their settlement agreement confidential under statutory provisions. The request cites 35 U.S.C. §317(b) and related Board rules to limit public disclosure.
Liberty Energy Inc. et al.vsU.S. Well Services, LLC et al.
Liberty Energy and Liberty Oilfield Services terminated an IPR against U.S. Well Services after a Covenant Not to Sue was executed, leading the Board to dismiss the case before any claims were instituted.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.